Phibro Animal Health Corporation to Participate at Stifel Jaws & Paws Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Stifel Jaws & Paws Conference.
Chief Operating Officer, Larry Miller along with Director and Executive Vice President, Corporate Strategy, Daniel Bendheim will address financial analysts and investors on Thursday, May 29, 2025, at 8:35 AM ET at the Lotte New York Hotel in New York.
The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.
Our filings with the Securities and Exchange Commission are available online at www.sec.gov, www.pahc.com or on request from the company.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 minutes ago
- Business Wire
Renesas Announces Expected Loss Resulting from Signing Restructuring Support Agreement with Wolfspeed
TOKYO--(BUSINESS WIRE)--Renesas Electronics Corporation (TSE: 6723, "Renesas"), a premier supplier of advanced semiconductor solutions, today announced that it has entered into a Restructuring Support Agreement (the "Restructuring Support Agreement") with Wolfspeed, Inc. (NYSE: WOLF, "Wolfspeed") and its principal creditors for the financial restructuring of Wolfspeed. As a result, Renesas expects to record a loss as described below. 1. Details of Loss As , Renesas entered into the silicon carbide wafer supply agreement with Wolfspeed, and through Renesas' wholly owned subsidiary in the United States, it provided a deposit (the "Deposit") of US$2 billion (approximately 292.0 billion yen) to Wolfspeed. In October 2024, Renesas and Wolfspeed amended their agreement and increased the outstanding principal amount of the Deposit to US$2.062 billion (approximately 301.1 billion yen). Subsequently, Wolfspeed has experienced financial challenges. On May 8, 2025, during its quarterly earnings call, Wolfspeed disclosed that to achieve its stated goal of strengthening its balance sheet, it may implement a transaction through an in-court solution. Due to Wolfspeed's contemplation of an in-court option, Wolfspeed included required going concern language in the footnotes to its financial statements for the quarterly period ended March 30, 2025. In response to this situation, Renesas has been engaging in discussions with Wolfspeed and today entered into the Restructuring Support Agreement among Wolfspeed and its principal creditors, pursuant to which Renesas agreed to, among other things, convert the Deposit of US$2.062 billion into convertible notes, common stock, and warrants issued by Wolfspeed as follows (the 'Restructuring'). Wolfspeed convertible notes: US$204 million (approximately 29.8 billion yen) in aggregate principal amount, convertible to Wolfspeed common stock, maturing in June 2031. These notes are convertible into 13.6% of Wolfspeed's total issued shares on a non-diluted basis at the time of the completion of the Restructuring. On a fully diluted basis, and prior to the exercise of the warrants to be granted to Renesas, this corresponds to 11.8%. Wolfspeed common stock: equivalent to 38.7% (17.9% on a fully diluted basis, prior to Renesas warrants exercise) of the total number of issued shares of Wolfspeed at the completion of the Restructuring. Wolfspeed warrants: equivalent to 5% (on a fully diluted basis) of the total number of issued shares of Wolfspeed at the completion of the Restructuring. The Restructuring is expected to be consummated through proceedings under Chapter 11 of the U.S. Bankruptcy Code. It is expected that Wolfspeed will file a petition with the court to initiate such proceedings in the near future. The Restructuring is expected to become effective by the end of September 2025, subject to court approval of the restructuring plan. If the necessary regulatory approvals have not been obtained by the time the Restructuring takes effect, Renesas will hold rights to instruments with equivalent economic value to Wolfspeed's convertible notes, common stock, and warrants until those approvals are received. In connection with the signing of the Restructuring Support Agreement, Renesas expects to record a loss on the deposited receivables related to the Deposit in its consolidated financial statements. Although the timing and amount of such loss have not been determined at this time, Renesas believes that there is a possibility of recording a loss of approximately 250 billion yen (converted at an average exchange rate of 150 yen to the dollar during the period) in the consolidated financial statements for the six months ending June 30, 2025. Please note that this amount is an estimate calculated by Renesas' internal analysis based on the currently available information and may increase or decrease due to various factors. The definitive timing and amount of the loss to be recorded will be determined in consultation with Renesas' auditor and will be announced once it is determined. 2. Future Outlook Renesas discloses revenue, gross margin, and operating margin on a "Non-GAAP" basis and does not disclose a forecast for profit attributable to owners of parent. Therefore, there is no change to the forecast for the six months ending June 30, 2025, announced on April 24, 2025. (Note1) Unless otherwise indicated, yen equivalents in this material are calculated using the exchange rate as of June 20, 2025: 146 yen to the dollar. (Note2) Non-GAAP figures are calculated by removing or adjusting non-recurring items and other adjustments from GAAP (IFRS basis) figures following a certain set of rules. Renesas believes non-GAAP measures provide useful information in understanding and evaluating its constant business results, and therefore, forecasts are provided on a non-GAAP basis. This adjustment and exclusion include the amortization of intangible assets recognized from acquisitions, other PPA (purchase price allocation) adjustments and stock-based compensation, as well as other non-recurring expenses and income Renesas believes to be applicable. Expand About Renesas Electronics Corporation Renesas Electronics Corporation (TSE: 6723) empowers a safer, smarter and more sustainable future where technology helps make our lives easier. A leading global provider of microcontrollers, Renesas combines our expertise in embedded processing, analog, power and connectivity to deliver complete semiconductor solutions. These Winning Combinations accelerate time to market for automotive, industrial, infrastructure and IoT applications, enabling billions of connected, intelligent devices that enhance the way people work and live. Learn more at Follow us on LinkedIn, Facebook, Twitter, YouTube, and Instagram. (FORWARD-LOOKING STATEMENTS) The statements in this press release with respect to the plans, strategies and financial outlook of Renesas and its consolidated subsidiaries (collectively 'we') are forward-looking statements involving risks and uncertainties. Such forward-looking statements do not represent any guarantee by management of future performance. In many cases, but not all, we use such words as 'aim,' 'anticipate,' 'believe,' 'continue,' 'endeavor,' 'estimate,' 'expect,' 'initiative,' 'intend,' 'may,' 'plan,' 'potential,' 'probability,' 'project,' 'risk,' 'seek,' 'should,' 'strive,' 'target,' 'will' and similar expressions to identify forward-looking statements. You can also identify forward-looking statements by discussions of strategy, plans or intentions. These statements discuss future expectations, identify strategies, contain projections of our results of operations or financial condition, or state other forward-looking information based on our current expectations, assumptions, estimates and projections about our business and industry, our future business strategies and the environment in which we will operate in the future. Known and unknown risks, uncertainties and other factors could cause our actual results, performance or achievements to differ materially from those contained or implied in any forward-looking statement, including, but not limited to, general economic conditions in our markets, which are primarily Japan, North America, Asia, and Europe; demand for, and competitive pricing pressure on, products and services in the marketplace; ability to continue to win acceptance of products and services in these highly competitive markets; fluctuations in currency exchange rates, particularly between the yen and the U.S. dollar; and risks and uncertainties associated with Wolfspeed's proceedings under Chapter 11 of the U.S. Bankruptcy Code, including Wolfspeed's ability to maintain relationships with suppliers, customers, employees and other third parties and regulatory authorities as a result of such proceedings, and other factors discussed in Wolfspeed's filings with the U.S. Securities and Exchange Commission. Among other factors, a downturn of the world economy; deteriorating financial conditions in world markets, or a deterioration in domestic and overseas stock markets, may cause actual results to differ from the projected results forecast. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. This press release is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither we nor our advisors or representatives are under an obligation to update, revise, or affirm.
CNBC
42 minutes ago
- CNBC
Bitcoin sinks below $99,000 as U.S. strikes on Iran trigger crypto market sell-off
Bitcoin fell to its lowest level since May over the weekend, as rising tensions in the Middle East and renewed inflation fears triggered a sharp selloff across digital assets. Bitcoin dropped below the $99,000 mark on Sunday — its lowest point in more than a month — as the crypto market became the first to react to escalating geopolitical risk. Bitcoin is trading around $99,380, down more than 2% over the past 24 hours, while ether has dropped 5% to below $2,200. Solana, XRP, and dogecoin also posted sharp losses, dragging the entire crypto complex deep into the red. The selloff appears to be a combination of geopolitical shock and macroeconomic concern. Iran has reportedly threatened to block the Strait of Hormuz — a vital shipping lane that handles about 20% of global oil supply. JPMorgan warns that a full closure could drive oil prices as high as $130 per barrel. One prominent macro research firm notes that such a spike could send U.S. inflation back toward 5% — a level not seen since March 2023, when the Fed was still actively raising rates. That outlook has traders reassessing the path of interest rates — and rotating out of speculative assets like crypto. While bitcoin is often pitched as an inflation hedge, it's currently behaving more like a high-beta tech stock. According to crypto data provider Kaiko, bitcoin's correlation with the tech-heavy Nasdaq has climbed sharply in recent weeks, after hitting a multi-month low earlier this year — a period that coincided with surging inflows into spot bitcoin ETFs. Institutional positioning also appears to have shifted. More than $1.04 billion flowed into spot bitcoin ETFs from Monday through Wednesday last week, according to data from CoinGlass. But those inflows collapsed heading into the weekend, with zero net movement Thursday and just $6.4 million on Friday — coinciding with President Donald Trump's early G7 departure and the announcement of a two-week review of U.S. options on Iran. The technical breakdown added fuel to the selloff. CoinGlass research shows bitcoin's drop below $99,000 triggered forced selling across offshore derivatives platforms like Binance and Bybit. At its peak on Sunday, more than $1 billion in crypto positions were liquidated during a 24-hour span — with over 95% coming from long bets, underscoring just how overexposed the market was heading into the weekend.
Business Wire
an hour ago
- Business Wire
New Data Show Delve Bio's Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
BOSTON--(BUSINESS WIRE)-- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing. "Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not and speed is critical' said Brad Murray, chief executive officer of Delve Bio. Among the data presented at the meeting is a comparison of Delve's metagenomic cerebrospinal fluid (CSF) test, Delve Detect CSF, compared to a traditional PCR-based meningitis/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner. 'This study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient's infection if mNGS were not included in the diagnostic workup,' said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. 'This study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections.' The study included 122 samples — 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS. The company's full presence at ASM Microbe 2025 includes: Delve's chief medical officer Steve Miller, M.D., Ph.D. hosted A New Era: Metagenomic Sequencing for Comprehensive Pathogen Detection, exploring real world evidence, clinical cases and considerations for laboratory teams implementing mNGS. Presentation of a case report in a feature poster, Using Metagenomic Sequencing to Diagnose a Novel Moraxella CNS Shunt Infection in a Culture-Negative Case Presentation of data comparing the company's mNGS CSF test, Delve Detect, to a widely used, PCR meningitis/encephalitis panel as part of the session Assessing the Clinical Impact of Next-Generation Sequencing: Where Are We Now? 'These presentations at ASM highlight the transformation underway in infectious disease diagnostics. Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical,' said Brad Murray, chief executive officer of Delve Bio. 'We're working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need.' Conference attendees are also invited to visit Delve Bio at booth #1440 to learn more about the company's metagenomic platform, including Delve Detect and its proprietary bioinformatics platform Delve Decide. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit
